Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Correction to: NSAID use and somatic exomic mutations in Barrett's esophagus.

Galipeau PC, Oman KM, Paulson TG, Sanchez CA, Zhang Q, Marty JA, Delrow JJ, Kuhner MK, Vaughan TL, Reid BJ, Li X.

Genome Med. 2019 Mar 12;11(1):14. doi: 10.1186/s13073-019-0625-y.

2.

NSAID use and somatic exomic mutations in Barrett's esophagus.

Galipeau PC, Oman KM, Paulson TG, Sanchez CA, Zhang Q, Marty JA, Delrow JJ, Kuhner MK, Vaughan TL, Reid BJ, Li X.

Genome Med. 2018 Feb 27;10(1):17. doi: 10.1186/s13073-018-0520-y. Erratum in: Genome Med. 2019 Mar 12;11(1):14.

3.

Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus.

Li X, Paulson TG, Galipeau PC, Sanchez CA, Liu K, Kuhner MK, Maley CC, Self SG, Vaughan TL, Reid BJ, Blount PL.

Cancer Prev Res (Phila). 2015 Sep;8(9):845-56. doi: 10.1158/1940-6207.CAPR-15-0130. Epub 2015 Jun 30.

4.

Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.

Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, Shaheen NJ, Hardie LJ, Romero Y, Bernstein L, Gammon MD, Casson AG, Bird NC, Risch HA, Ye W, Liu G, Corley DA, Blount PL, Fitzgerald RC, Whiteman DC, Wu AH, Reid BJ, Vaughan TL.

Carcinogenesis. 2014 Dec;35(12):2740-7. doi: 10.1093/carcin/bgu207. Epub 2014 Oct 3.

5.

Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus.

Li X, Galipeau PC, Paulson TG, Sanchez CA, Arnaudo J, Liu K, Sather CL, Kostadinov RL, Odze RD, Kuhner MK, Maley CC, Self SG, Vaughan TL, Blount PL, Reid BJ.

Cancer Prev Res (Phila). 2014 Jan;7(1):114-27. doi: 10.1158/1940-6207.CAPR-13-0289. Epub 2013 Nov 19.

6.

NSAIDs modulate clonal evolution in Barrett's esophagus.

Kostadinov RL, Kuhner MK, Li X, Sanchez CA, Galipeau PC, Paulson TG, Sather CL, Srivastava A, Odze RD, Blount PL, Vaughan TL, Reid BJ, Maley CC.

PLoS Genet. 2013 Jun;9(6):e1003553. doi: 10.1371/journal.pgen.1003553. Epub 2013 Jun 13.

7.

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.

Reid BJ, Li X, Galipeau PC, Vaughan TL.

Nat Rev Cancer. 2010 Feb;10(2):87-101. doi: 10.1038/nrc2773. Review.

8.

Translation of an STR-based biomarker into a clinically compatible SNP-based platform for loss of heterozygosity.

Kissel HD, Galipeau PC, Li X, Reid BJ.

Cancer Biomark. 2009;5(3):143-58. doi: 10.3233/CBM-2009-0618.

9.

Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.

Li X, Galipeau PC, Sanchez CA, Blount PL, Maley CC, Arnaudo J, Peiffer DA, Pokholok D, Gunderson KL, Reid BJ.

Cancer Prev Res (Phila). 2008 Nov;1(6):413-23. doi: 10.1158/1940-6207.CAPR-08-0121.

10.

p16 mutation spectrum in the premalignant condition Barrett's esophagus.

Paulson TG, Galipeau PC, Xu L, Kissel HD, Li X, Blount PL, Sanchez CA, Odze RD, Reid BJ.

PLoS One. 2008;3(11):e3809. doi: 10.1371/journal.pone.0003809. Epub 2008 Nov 27.

11.

Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.

Chao DL, Sanchez CA, Galipeau PC, Blount PL, Paulson TG, Cowan DS, Ayub K, Odze RD, Rabinovitch PS, Reid BJ.

Clin Cancer Res. 2008 Nov 1;14(21):6988-95. doi: 10.1158/1078-0432.CCR-07-5063.

12.

Direct inference of SNP heterozygosity rates and resolution of LOH detection.

Li X, Self SG, Galipeau PC, Paulson TG, Reid BJ.

PLoS Comput Biol. 2007 Nov;3(11):e244.

13.

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ.

PLoS Med. 2007 Feb;4(2):e67.

14.

Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.

Chao DL, Maley CC, Wu X, Farrow DC, Galipeau PC, Sanchez CA, Paulson TG, Rabinovitch PS, Reid BJ, Spitz MR, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40.

15.

Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.

Lomo LC, Blount PL, Sanchez CA, Li X, Galipeau PC, Cowan DS, Ayub K, Rabinovitch PS, Reid BJ, Odze RD.

Am J Surg Pathol. 2006 Apr;30(4):423-35.

PMID:
16625087
16.

Genetic clonal diversity predicts progression to esophageal adenocarcinoma.

Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ.

Nat Genet. 2006 Apr;38(4):468-73. Epub 2006 Mar 26.

PMID:
16565718
17.

Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.

Wongsurawat VJ, Finley JC, Galipeau PC, Sanchez CA, Maley CC, Li X, Blount PL, Odze RD, Rabinovitch PS, Reid BJ.

Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16.

18.

The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.

Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, Reid BJ.

Cancer Res. 2004 Oct 15;64(20):7629-33.

19.

Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus.

Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ.

Cancer Res. 2004 May 15;64(10):3414-27.

20.

Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.

Rudolph RE, Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ.

J Natl Cancer Inst. 2003 May 21;95(10):750-7.

21.

Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.

Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ.

Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52.

22.

p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.

Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ.

Cancer Res. 2001 Nov 15;61(22):8284-9.

23.

Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS.

Am J Gastroenterol. 2001 Oct;96(10):2839-48.

24.

Loss of heterozygosity in childhood de novo acute myelogenous leukemia.

Sweetser DA, Chen CS, Blomberg AA, Flowers DA, Galipeau PC, Barrett MT, Heerema NA, Buckley J, Woods WG, Bernstein ID, Reid BJ.

Blood. 2001 Aug 15;98(4):1188-94.

PMID:
11493469
25.

Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays.

Mei R, Galipeau PC, Prass C, Berno A, Ghandour G, Patil N, Wolff RK, Chee MS, Reid BJ, Lockhart DJ.

Genome Res. 2000 Aug;10(8):1126-37.

26.

Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.

Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ.

J Natl Cancer Inst. 1999 Dec 15;91(24):2087-95.

27.

p53-mutant clones and field effects in Barrett's esophagus.

Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ.

Cancer Res. 1999 Oct 1;59(19):4784-7.

28.
29.

Evolution of neoplastic cell lineages in Barrett oesophagus.

Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ.

Nat Genet. 1999 May;22(1):106-9.

30.

Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities.

Palanca-Wessels MC, Barrett MT, Galipeau PC, Rohrer KL, Reid BJ, Rabinovitch PS.

Gastroenterology. 1998 Feb;114(2):295-304.

PMID:
9453489
31.

Barrett's esophagus: ordering the events that lead to cancer.

Reid BJ, Barrett MT, Galipeau PC, Sanchez CA, Neshat K, Cowan DS, Levine DS.

Eur J Cancer Prev. 1996 Dec;5 Suppl 2:57-65. No abstract available.

PMID:
9061296
32.

Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.

Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ.

Oncogene. 1996 Nov 7;13(9):1867-73.

PMID:
8934532
33.

17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.

Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, Rabinovitch PS, Reid BJ.

Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4.

34.
35.

p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia.

Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, Reid BJ.

Gastroenterology. 1994 Jun;106(6):1589-95.

PMID:
8194706
36.

17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy.

Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, Suzuki H, Abraham JM, Meltzer SJ, Reid BJ.

Cancer Res. 1994 May 1;54(9):2292-5.

37.

Barrett's esophagus: the biology of neoplastic progression.

Neshat K, Sanchez CA, Galipeau PC, Levine DS, Reid BJ.

Gastroenterol Clin Biol. 1994;18(1 Pt 2):D71-6. Review. No abstract available.

PMID:
8013790
38.

Barrett's esophagus: a model of human neoplastic progression.

Neshat K, Sanchez CA, Galipeau PC, Cowan DS, Ramel S, Levine DS, Reid BJ.

Cold Spring Harb Symp Quant Biol. 1994;59:577-83. Review. No abstract available.

PMID:
7587115

Supplemental Content

Loading ...
Support Center